Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 9187213.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intravenous haloperidol is recommended as the drug of choice to treat delirium in ICU patients. Movement disorders and other adverse events commonly occur with oral haloperidol use but are rarely seen with IV haloperidol use, and withdrawal symptoms have not been reported with short-term ICU use. We describe self-limited dyskinesia during withdrawal of high-dose continuous IV haloperidol therapy in five ICU patients.
Medical subject headings
- Critical Care
- Delirium
- Dyskinesia, Drug-Induced
- Haloperidol
- Substance Withdrawal Syndrome